Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00225914 · ClinicalTrials.gov registry record · Phase 4
Study of Paxil Use in Menopausal Women
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 64
- Enrollment target
NCT00225914: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT00225914 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 64 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00225914, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 64 participants
- Enrollment target
Study Summary
To evaluate the efficacy, safety, and tolerability of Paroxetine treatment in perimenopausal and postmenopausal women who present with menopause-related symptoms after discontinuing hormone therapy (HT), in the presence or absence of concomitant symptoms of depression or anxiety.
Interventions
- DRUG placebo
- DRUG Paroxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2004-09 |
| Est. Completion | 2006-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00225914
The ClinicalTrials.gov registry entry for NCT00225914 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00225914 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00225914 about?
NCT00225914 is a clinical study titled "Study of Paxil Use in Menopausal Women". To evaluate the efficacy, safety, and tolerability of Paroxetine treatment in perimenopausal and postmenopausal women who present with menopause-related symptoms after discontinuing hormone therapy (HT), in the presence or absence of concomitant symptoms of depression or anxiety.
What is the current status of trial NCT00225914?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 64 participants. The study started on 2004-09. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00225914?
The interventions under investigation include: placebo (DRUG), Paroxetine (DRUG).
Who is sponsoring clinical trial NCT00225914?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.